Belgoprocess and PanTera Join Forces to Produce Innovative Cancer Therapy: New Operational and Strategic MilestonesIn the fight against cancer, Belgium’s nuclear technology sector and the nuclear industry are once again making significant progress. Last week, Belgoprocess and PanTera reached two important milestones in their collaboration. Belgoprocess has successfully begun opening a new batch of thorium-229 (Th-229) capsules sourced from PanTera’s international partner, while both organizations also signed a long-term agreement for the purification of PanTera’s radium. This collaboration strengthens Belgium’s position as a global leader in innovation in nuclear medicine.Read more PANTERA ISSUES A CLARIFICATION REGARDING STATEMENTS PUBLISHED IN THE TRADE PRESSDetails available by clicking the button "Read More"Read more TerraPower Isotopes and PanTera, supported by IRE, Expand Collaboration to Boost Global Actinium-225 SupplyNew facilities in Belgium will bolster production efforts for critical isotope in next‑generation cancer treatment Read more PanTera achieves Major Regulatory Milestone for its Actinium-225 ProductionPanTera announced today that it has reached three critical regulatory milestones in its mission to bring new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for precision treatment. These achievements underscore the company’s commitment to regulatory compliance, and advancing life-saving therapies, starting with the actinium-225 (Ac-225) based Targeted Alpha Therapy (TAT). 14/04/2026Read more PanTera Breaks Ground on its Actinium Production Center (APC)This milestone marks the start of a new era in global Ac-225 supply for targeted alpha therapyRead more PanTera secures two key permits for Actinium-225 Production Facility in MolTwo key permits required to initiate construction of its state-of-the-art Actinium-225 (Ac-225) Production Center (APC) in Mol, Belgium have been granted to PanTera. The environmental permit was granted by the Province of Antwerp, and the nuclear permit by the Federal Agency for Nuclear Control (FANC/AFCN), the two permits mark a critical step forward in PanTera’s mission to secure a global supply of Ac-225 for targeted alpha therapy in cancer treatment.Read more PanTera produces and supplies first Actinium-225 extracted from Thorium-229 in BelgiumIn June 2025, PanTera has successfully extracted and supplied Actinium-225 (Ac-225) from its Thorium-229 (Th-229) generator, installed at its production facility in Belgium. This achievement marks the first delivery of Ac-225 under PanTera’s "Early Supply" program, powered by Th-229 material provided by TerraPower Isotopes.Read more PanTera signs an agreement with SK Biopharmaceuticals for the supply of actinium-225On February 25, 2025, SK Biopharmaceuticals announced their collaboration with PanTera marking a significant step forward in the global interest surrounding Actinium-225.
This partnership leverages PanTera's expertise in delivering high-purity Actinium-225, a crucial resource for innovative therapeutic applications for cancer treatments.26/02/2025Read more 
